

NORRIS MEDICINES LIMITED

Regd Off: 801/P, GIDC Estate, Ankleshwar, 393002, Gujarat.

Phone: 02646-223462 Fax 02646 -250126.

email: contact@norrispharma.com. Website: www.norrispharma.com

CIN No.,L24230GJ1990PLC086581

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.12.2024							
Rs. In Lakhs							
Sl. No.	Particulars	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	(a) Revenue from Operations	110.60	126.84	64.63	309.93	414.80	563.56
	(b) Other Income	0.33	0.12	-	1.61	0.00	2.84
	Total Income From Operations (Net)	110.93	126.96	64.63	311.54	414.80	566.40
2	Expenses						
	a. Cost of Materials Consumed	93.99	17.51	12.82	179.12	254.17	315.93
	b. Changes in Inventories of Finished Goods, work in Progress and stock in trade	-35.39	75.35	-7.40	-10.41	-10.38	-50.04
	c. Employee Benefit Expenses	26.01	28.95	33.70	89.27	141.09	182.05
	d. Finance Costs	12.49	8.48	8.61	29.42	25.84	36.98
	e. Depreciation and Amortisation Expense	13.29	13.29	14.48	39.76	43.28	57.15
	f. Other expenditure	28.71	19.49	29.47	85.28	96.95	134.12
	Total Expenses	139.10	163.07	91.69	412.44	550.95	676.19
3	Profit/ Loss before Tax (1-2)	-28.17	-36.11	-27.05	-100.90	-136.15	-109.79
4	Tax Expense						
	a: Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	b: Deferred Tax	0.00	0.00	0.00	0.00	0.00	8.89
5	Profit / Loss after Tax	-28.17	-36.11	-27.05	-100.90	-136.15	-118.68
6	Other Comprehensive Income						
a.	(i) Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	0.00
b.	(i) Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	0.00
7	Total Comprehensive Income for the period	-28.17	-36.11	-27.05	-100.90	-136.15	-118.68
8	Paid-up equity share capital (Face Value of Rs. 10/- each)	992.58	992.58	992.58	992.58	992.58	992.58
9	- Basic and diluted	-0.28	-0.36	-0.27	-1.02	-1.36	-1.20

Notes:

- 1) The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 13/02/2025. The above results have been subjected to Limited Review by the Statutory Auditors of the Company.
- 2) The Financial results of the Company have been prepared with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation,2015 and SEBI circular dated 05.07.2016.
- 3) The Company is having one segment only and therefore Segmental Reporting is not applicable.
- 4) There are no exceptional/ extraordinary items during the quarter ended 31.12.2024
- 5) Previous year/ period figures have been regrouped /rearranged wherever necessary to make them comparable with current period figures.

Date: 13.02.2025
Place: Ankleshwar

For Norris Medicines Limited


Vimal D Shah
Director

